

## Amendments to the Claims

**1. (Original)** A DNA or RNA localized in the cytoplasm having the 3'-terminus or 5'-terminus chemically modified with a group represented by the formula

-PO(OH)-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>NH-CO-peptide or  
-O-CO-NH-CH<sub>2</sub>CH<sub>2</sub>NHCONH(CH<sub>2</sub>)<sub>6</sub>NH-CO-NH-peptide.

**2. (Currently amended)** The DNA or RNA localized in the cytoplasm according to claim 1 modified with a wherein the peptide that is a signal peptide selected from HIV-1 Rev (SEQ ID NO: 1 in Sequence Listing), PKI $\alpha$  (SEQ ID NO: 2 in Sequence Listing), MAPKK (SEQ ID NO: 3 in Sequence Listing), and Dsk-1 (SEQ ID NO: 4 in Sequence Listing), or a membrane fusion peptide selected form an HIV-1 tat C-terminal membrane fusion peptide (SEQ ID NO: 5 in Sequence Listing), a gp-41 membrane fusion peptide (SEQ ID NO: 6 in Sequence Listing), an artificially designed amphipathic  $\alpha$ -helical peptide (SEQ ID NO: 7 in Sequence Listing), and an artificially designed amphipathic  $\beta$ -sheet peptide (SEQ ID NO: 8, 14, or 15 in Sequence Listing).

**3. (Currently amended)** The DNA localized in the cytoplasm according to claim 1 ~~or 2~~, wherein the DNA is an oligo DNA that exhibits a genetic medicinal activity.

**4. (Currently amended)** The RNA localized in the cytoplasm according to claim 1 ~~or 2~~, wherein the RNA is an oligo RNA that exhibits a genetic medicinal activity.

**5-8. (Cancelled)**

**9. (Currently amended)** A siRNA localized in the cytoplasm wherein characterized in that a chemical modification group is introduced into the 5'-terminus of at least one of the sense strand and the antisense strand constituting the double-strand or a dangling end of the antisense strand, or both.

**10. (Currently amended)** A siRNA localized in the cytoplasm wherein characterized ~~in that~~ at least one of the sense strand and the antisense strand contains a chemical modification group at a non-terminal position.

**11. (Currently amended)** The siRNA localized in the cytoplasm according to claim 9 or 10, wherein the chemical modification group has a polyamine molecule bonded thereto.

**12. (Currently amended)** The siRNA localized in the cytoplasm according to claim 9 or 10, wherein the chemical modification group is a nuclear export signal peptide or membrane fusion peptide introduced via a bifunctional linker.

**13. (Original)** The siRNA localized in the cytoplasm according to claim 12, wherein the bifunctional linker is a residue of a divalent chemical modification group.

**14. (New)** The siRNA localized in the cytoplasm according to claim 9 or 10, wherein the chemical modification group has a polyamine molecule bonded thereto.

**15. (New)** The siRNA localized in the cytoplasm according to claim 9 or 10, wherein the chemical modification group is a nuclear export signal peptide or membrane fusion peptide introduced via a bifunctional linker.

**16. (New)** The siRNA localized in the cytoplasm according to claim 15, wherein the bifunctional linker is a residue of a divalent chemical modification group.